Abstract
Serum levels of pro-[vascular endothelial growth factor (VEGF)] and anti-[thrombospondin-1 (TSP)] angiogenic cytokines were prospectively measured in a phase II trial of chemoimmunotherapy (CIT) for chronic lymphocytic leukaemia (CLL) patients (n = 56). Pretreatment VEGF levels were lower among patients who achieved complete remission (CR) or nodular partial remission (nPR) relative to those with partial remission (PR) or stable/progressive disease (median 122.0 pg/ml vs. 246.8 pg/ml; P = 0.03). VEGF:TSP ratio was lower (anti-angiogenic phenotype) among patients who achieved CR/nPR. The pretreatment VEGF:TSP ratio also correlated with overall survival (P = 0.008). A pro-angiogenic profile appears associated with diminished response and inferior survival in CLL patients receiving CIT.
Publication types
-
Clinical Trial, Phase II
-
Research Support, N.I.H., Extramural
-
Research Support, Non-U.S. Gov't
MeSH terms
-
Antibodies, Monoclonal / therapeutic use
-
Antibodies, Monoclonal, Murine-Derived
-
Antineoplastic Agents / therapeutic use
-
Combined Modality Therapy
-
Cyclophosphamide / therapeutic use
-
Fibroblast Growth Factors / blood*
-
Humans
-
Immunotherapy
-
Leukemia, Lymphocytic, Chronic, B-Cell / blood*
-
Leukemia, Lymphocytic, Chronic, B-Cell / therapy
-
Pentostatin / therapeutic use
-
Prognosis
-
Prospective Studies
-
Rituximab
-
Thrombospondin 1 / blood*
-
Vascular Endothelial Growth Factors / blood*
Substances
-
Antibodies, Monoclonal
-
Antibodies, Monoclonal, Murine-Derived
-
Antineoplastic Agents
-
Thrombospondin 1
-
Vascular Endothelial Growth Factors
-
Pentostatin
-
Rituximab
-
Fibroblast Growth Factors
-
Cyclophosphamide